A recent report has also shown that many neuroendocrine cancers, including neuroblastoma, use PRC2 to repress MHC-I antigen-processing pathway (MHC-I APP) genes, thereby evading immune surveillance55. This evidence concerns the gene APP and neuroblastoma.